Meta-Analysis of Efficacy of Concurrent Chemoradiotherapy Combined with Anti-EGFR Drugs in Locally Advanced Esophageal Cancer
LIU Ying
KONG De-jiu
HU Xiao-chen
ZHANG Jia-cheng
SHEN Shen
ZHANG jie-chong
YUAN Xiang
WANG Xin-shuai
Abstract：Objective To compare the efficacy of concurrent chemoradiotherapy with or without anti-EG-FR drugs in patients with locally advanced esophageal cancer.Methods PubMed,Embase,Cochrane Li-brary,Web of Science,CNKI,VIP,Wanfang were retrieved,and the literatures that meet the standards were screened and included.RevMan5.4.1 statistical software was used to test the heterogeneity of studies,and the corresponding effect models were selected to merge the effect values,and funnel plots were drawn to eval-uate the publication bias.Results 8 articles and 10 groups of controlled clinical trials were included,in-volving a sample size of 1806 patients,including 896 in the experimental group and 910 in the control group.The analysis results showed that there was no significant difference in OS of patients with concurrent chemora-diotherapy combined with targeted drugs(HR=0.87,95％CI:0.72～1.06,P=0.17),erlotinib combined with concurrent chemoradiotherapy significantly improved the OS of patients(HR=0.72,95％CI:0.62-0.83,P＜0.0001),while cetuximab combined with concurrent chemoradiotherapy had no significant differ-ence in OS(HR=1.05,95％CI:0.78～1.41,P=0.77).Conclusion For patients with advanced esopha-geal cancer,concurrent chemoradiotherapy combined with erlotinib can significantly improve the OS of pa-tients and have significant survival benefits.
Keywords：esophagus cancerchemoradiotherapyEGFRerlotinibMeta-analysis
Publication Date：2023-12-30
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：6( 315-320 )